Matthew R. Patterson

Chairman at Vor Biopharma

Matt Patterson is a biotechnology executive with nearly 30 years of experience in the research, development, and commercialization of innovative therapeutics and has held positions of senior management in both private and public biotechnology companies. Matt co-founded Audentes Therapeutics and served as Chief Executive Officer from the Company’s inception in November 2012 until its acquisition by Astellas Pharma Inc. in January 2020. He was also Chairman of the Board of Directors and formerly served as President until May 2018. Previously, Matt worked for Genzyme Corporation, BioMarin Pharmaceutical, and Amicus Therapeutics. Prior to Audentes he was an Entrepreneur-In-Residence with OrbiMed.

Matt is a member of the Board of Directors of Homology Medicines, Inc., Inc., Remix Therapeutics, Inc., and 5:01 Acquisition Corporation. He also served as a member of the Board of Directors of the Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the gene and cell therapy and broader regenerative medicine sector, from 2015-2021, and was Chairman in 2019 and 2020. Matt received his bachelor’s degree in biochemistry from Bowdoin College.

Links